CUEYY Stock | News | Quote | Stock Forum | Monday, October 7,

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Kohl's Corporation Faces Significant Challenges Kohl's Corporation (NYSE: KSS) has recently seen its stock plummet to a concerning 52-week low of $13.61. This decline paints a grim picture of the current retail environment, where shifting consumer habits and fierce competition play a pivotal role. Priced at just 0.4 times book value and boasting a generous 14.5% dividend...

Financial Performance Highlights for Rapid Micro Biosystems Rapid Micro Biosystems, Inc. (NASDAQ: RPID) has announced impressive results for the fourth quarter and the entire fiscal year of 2024. The company recorded a total revenue of $8.2 million in the fourth quarter, marking a 30% increase compared to the same period in 2023. Likewise, the full year revenue reached...

ALZpath and Siemens Healthineers Form Strategic Partnership ALZpath is thrilled to announce a significant licensing agreement with Siemens Healthineers. This collaboration marks a pivotal enhancement in the accessibility of diagnostic testing for Alzheimer's disease. The agreement involves the use of ALZpath's proprietary pTau217 antibody, a remarkable tool for...

Results from Phase 1 Trials of GB-0895 Unveiled Generate:Biomedicines is making notable headlines with its innovative drug GB-0895. This cutting-edge treatment is an ultra-high affinity anti-TSLP monoclonal antibody, specifically designed for individuals grappling with asthma. With a unique formulation, GB-0895 offers a prolonged half-life and sustained pharmacological...

Steady Growth in the Natural Stone Market The natural stone market is on a promising upward trajectory, predicted to rise from USD 37.89 billion to USD 47.63 billion by a future date, indicating a compound annual growth rate (CAGR) of 4.68%. Various factors are driving this growth, most notably the intense infrastructure investment blooming worldwide. The construction...